منابع مشابه
Brentuximab Vedotin (SGN-35).
Brentuximab vedotin (SGN-35) is an antibody-drug conjugate (ADC) directed against the CD30 antigen expressed on Hodgkin lymphoma and anaplastic large cell lymphoma. SGN-35 consists of the cAC10 chimerized IgG1 monoclonal antibody SGN30, modified by the addition of a valine-citrulline dipeptide linker to permit attachment of the potent inhibitor of microtubule polymerization monomethylauristatin...
متن کاملBrentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.
BACKGROUND Hodgkin's lymphoma and anaplastic large-cell lymphoma are the two most common tumors expressing CD30. Previous attempts to target the CD30 antigen with monoclonal-based therapies have shown minimal activity. To enhance the antitumor activity of CD30-directed therapy, the antitubulin agent monomethyl auristatin E (MMAE) was attached to a CD30-specific monoclonal antibody by an enzyme-...
متن کاملIncreased Efficacy of Brentuximab Vedotin (SGN-35) in Combination with Cytokine-Induced Killer Cells in Lymphoma
Brentuximab vedotin (SGN-35) is an antibody-drug conjugate with a high selectivity against CD30⁺ cell lines and more than 300-fold less activity against antigen-negative cells. In the last years, the results of many in vitro and in vivo studies have led to the fast approval of this drug to treat lymphoma patients. Another innovative method to treat tumor cells including lymphoma cells is the us...
متن کاملBlood Spotlight Brentuximab vedotin
Delivery of cytotoxic agents specifically to malignant cells has always been a goal of cancer therapy. With the development of monoclonal antibodies for clinical use, this goal has become a reality, and antibody-drug conjugates are now part of standard therapy in diseases such as lymphoma and breast cancer. Brentuximab vedotin, which targets CD30, has contributed to the success of antibody-drug...
متن کاملBrentuximab vedotin: axonal microtubule's Apollyon
Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most common side effects encountered in patients treated with chemotherapeutic drugs binding to soluble tubulin or targeting microtubules. Some of these drugs, such as taxanes and ixabepilone, stabilize and block microtubule remodeling, whereas others, including Vinca alkaloids, colchicine and eribulin, promote microtubule disassem...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Cancer Research
سال: 2011
ISSN: 1078-0432,1557-3265
DOI: 10.1158/1078-0432.ccr-11-0488